Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2010 May 01;1602:334-45. doi: 10.1111/j.1476-5381.2010.00682.x.
Show Gene links
Show Anatomy links
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H, Shrikhande A, Ward KM, Tingley FD, Coe JW, O'Neill BT, Tseng E, Wang EQ, Mather RJ, Hurst RS, Williams KE, de Vries M, Cremers T, Bertrand S, Bertrand D.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: Smoking cessation trials with three high-affinity partial agonists of alpha4beta2 neuronal nicotinic acetylcholine receptors (nAChRs) have demonstrated differences in their clinical efficacy. This work examines the origin of the differences by taking into account brain exposure and pharmacological effects at human alpha4beta2 nAChRs.
EXPERIMENTAL APPROACH: Rat plasma and brain pharmacokinetics were characterized and used to predict human steady-state plasma and brain concentrations following recommended doses of each of the three compounds. The pharmacological characterization included in vitro affinities at different nAChR subtypes, functional efficacies and potencies at the human alpha4beta2 nAChR, as well as in vivo effects on rat mesolimbic dopamine turn-over.
KEY RESULTS: A comparison of predicted human brain concentrations following therapeutic doses demonstrated that varenicline and nicotine, but not dianicline and cytisine, can extensively desensitize and, to a lesser extent, activate alpha4beta2 nAChRs. The limited clinical efficacy of dianicline may be accounted for by a combination of weak functional potency at alpha4beta2 nAChRs and moderate brain penetration, while recommended doses of cytisine, despite its high in vitro potency, are predicted to result in brain concentrations that are insufficient to affect alpha4beta2 nAChRs.
CONCLUSIONS AND IMPLICATIONS: The data provide a plausible explanation for the higher abstinence rate in smoking cessation trials following treatment with varenicline than with the two other alpha4beta2 nAChR partial agonists. In addition, this retrospective analysis demonstrates the usefulness of combining in vitro and in vivo parameters with estimated therapeutic human brain concentrations for translation to clinical efficacy.
Benowitz,
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
2009, Pubmed
Benowitz,
Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics.
2009,
Pubmed Briggs,
Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists.
1998,
Pubmed
,
Xenbase Buisson,
Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function.
2001,
Pubmed Burstein,
Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers.
2006,
Pubmed Cahill,
Nicotine receptor partial agonists for smoking cessation.
2007,
Pubmed Cahill,
Nicotine receptor partial agonists for smoking cessation.
2008,
Pubmed Coe,
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
2005,
Pubmed
,
Xenbase Cohen,
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
2003,
Pubmed
,
Xenbase Cremers,
Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique.
2009,
Pubmed Drenan,
In vivo activation of midbrain dopamine neurons via sensitized, high-affinity alpha 6 nicotinic acetylcholine receptors.
2008,
Pubmed Etter,
Cytisine for smoking cessation: a literature review and a meta-analysis.
,
Pubmed Exley,
Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens.
2008,
Pubmed Faessel,
Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers.
2006,
Pubmed Faessel,
Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers.
2006,
Pubmed Fagerström,
Neuropharmacology and potential efficacy of new treatments for tobacco dependence.
2006,
Pubmed Grady,
Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.
2009,
Pubmed Hoda,
Human nocturnal frontal lobe epilepsy: pharmocogenomic profiles of pathogenic nicotinic acetylcholine receptor beta-subunit mutations outside the ion channel pore.
2008,
Pubmed
,
Xenbase Hogg,
Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors.
2007,
Pubmed Hogg,
Nicotinic acetylcholine receptors as drug targets.
2004,
Pubmed Hosea,
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.
2009,
Pubmed Kalvass,
Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.
2002,
Pubmed Laviolette,
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour.
2004,
Pubmed Livingstone,
alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex.
2009,
Pubmed Mansvelder,
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas.
2002,
Pubmed Mansvelder,
Cellular and synaptic mechanisms of nicotine addiction.
2002,
Pubmed Marubio,
Effects of nicotine in the dopaminergic system of mice lacking the alpha4 subunit of neuronal nicotinic acetylcholine receptors.
2003,
Pubmed Maskos,
Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors.
2005,
Pubmed Mihalak,
Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
2006,
Pubmed
,
Xenbase Nides,
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis.
2008,
Pubmed NULL,
Guide to Receptors and Channels (GRAC), 4th Edition.
2009,
Pubmed Papke,
Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit.
1994,
Pubmed
,
Xenbase Picciotto,
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood.
2008,
Pubmed Picciotto,
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine.
1998,
Pubmed Pons,
Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration.
2008,
Pubmed Reavill,
Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline.
1990,
Pubmed Reed-Hagen,
Pharmacokinetics of ezlopitant, a novel non-peptidic neurokinin-1 receptor antagonist in preclinical species and metabolite kinetics of the pharmacologically active metabolites.
1999,
Pubmed Rollema,
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
2007,
Pubmed Rollema,
Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation.
2007,
Pubmed Rose,
Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction.
1999,
Pubmed Salas,
Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice.
2009,
Pubmed Smith,
Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
2007,
Pubmed Tutka,
Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy.
2006,
Pubmed
